It is made available under a CC-BY-NC-ND 4.0 International license .

1	Circulating microRNA profiles in early-stage osteoarthritis and rheumatoid arthritis
2	
3	Madhu Baghel ¹ *, Thomas Wilson ¹ *, Michelle Ormseth ^{2,3} , Patrick Yousif ⁴ , Ayad Alkhatib ⁴ , Alireza
4	Meysami ⁴ , Jason Davis ⁵ , Vasilios Moutzouros ⁵ , Shabana Amanda Ali ^{1,6**}
5	
6	Affiliations
7	
8	¹ Bone and Joint Center, Henry Ford Health + Michigan State University Health Sciences,
9	Detroit, Michigan, USA
10	² Vanderbilt University Medical Center, Nashville, Tennessee, USA
11	³ Tennessee Valley Health System, Nashville Campus VA Medical Center, Nashville,
12	Tennessee, USA
13	⁴ Department of Rheumatology, Henry Ford Health, Detroit, Michigan, USA
14	⁵ Department of Orthopedic Surgery, Henry Ford Health, Detroit, Michigan, USA
15	⁶ Center for Molecular Medicine and Genetics, Wayne State University, Detroit, Michigan, USA
16	*Co-first authors
17	**Corresponding author:
18	Shabana Amanda Ali, PhD
19	Bone and Joint Center, Henry Ford Health + Michigan State University Health Sciences,
20	6135 Woodward Avenue, Detroit MI 48202, USA
21	Email: sali14@hfhs.org
22	Office: 313-874-8389
23	
24	
25	
26	

It is made available under a CC-BY-NC-ND 4.0 International license .

27 Abstract

28

Background: Osteoarthritis (OA) and rheumatoid arthritis (RA) are prevalent forms of arthritis.
Early detection of OA and RA is challenging with existing methods, which can delay effective
management. MicroRNAs are small molecules that have emerged as promising disease
biomarkers with the potential to improve early detection and differentiation of arthritis subtypes.
In this study we aimed to identify distinct circulating microRNAs in plasma from individuals with
early OA and early RA, using an unbiased microRNA-sequencing approach.

35

36 **Methods:** Plasma samples were collected from three study groups including: (a) early OA (N=20). 37 individuals with knee OA symptoms and radiographic Kellgren-Lawrence grade 0 or 1; (b) early RA (N=12), treatment-naïve individuals with <6 months of RA symptoms in any joint; and (c) non-38 OA/RA (N=44), individuals with no history of arthritis. Of these, N=62 samples were subjected to 39 40 microRNA-sequencing and analysis using a previously optimized pipeline. Exploratory analyses were followed by a stepwise filtering approach to shortlist both known (documented in miRBase 41 v22.1) and novel (predicted using bioinformatics) microRNAs. Prioritized microRNAs were then 42 43 validated via real-time qPCR (RT-qPCR) in N=14 independent samples.

44

Results: Principal component analyses revealed clustering of early OA versus both early RA and non-OA/RA groups, but not between early RA and non-OA/RA. In early OA, n=170 differentially expressed (DE) microRNAs were identified compared to both early RA and non-OA/RA, while no significant differences were found between early RA and non-OA/RA. Of these DE microRNAs, stepwise filtering and RT-qPCR validation identified dysregulation of six known microRNAs between early OA and early RA. Of these six microRNAs, two were upregulated in early OA, including hsa-miR-16-5p and hsa-miR-29c-3p, and four were upregulated in early RA, including

It is made available under a CC-BY-NC-ND 4.0 International license .

52	hsa-miR-744-5p, hsa-miR-382-5p, hsa-miR-3074-5p, and hsa-miR-11400. Additionally, one
53	novel microRNA sequence was found to be enriched in early OA and four in early RA.
54	
55	Conclusion: We identified a total of six known and five novel circulating microRNAs that differ
56	between early OA and early RA individuals. Validation of these microRNAs in independent
57	cohorts is warranted to establish their biomarker potential for distinguishing individuals with early
58	OA versus early RA.
59	
60	Keywords:
61	Plasma; microRNA-sequencing; novel microRNAs; biomarker; human
62	
63	
64	
65	
66	
67	
68	
69	
70	
71	
72	
73	
74	
75	
76	
77	

It is made available under a CC-BY-NC-ND 4.0 International license .

78 Background

79

Arthritis is a leading cause of joint pain and disability that encompasses over 100 subtypes (1). 80 81 Among these, osteoarthritis (OA) and rheumatoid arthritis (RA) are the most common, with a 82 global prevalence of 6.5% and 0.5-1%, respectively (2-4). Both conditions can affect a range of joints, from small phalangeal joints to larger weight-bearing joints, and both are driven by a 83 multifactorial etiology involving genetic, epigenetic, and environmental factors (5, 6). OA is the 84 85 most common type of non-autoimmune arthritis, primarily characterized by tissue destruction (5, 86 7). RA is the most common type of autoimmune arthritis, primarily characterized by joint inflammation (8). Although the pathophysiology of OA and RA differs, the initial presentation (e.g., 87 symptoms such as joint pain) can overlap significantly, particularly in cases of single-joint disease 88 (9-11). This creates a challenge for accurate diagnosis which is important in early stages of 89 90 disease to enable timely implementation of appropriate interventions, including exercise for OA 91 (12) and disease-modifying anti-rheumatic drugs (DMARDs) for RA (13).

92

Currently, diagnosis and staging criteria for OA rely on imaging, such as the Kellgren-Lawrence 93 94 (KL) radiographic grading scale (11). For RA, diagnosis involves four domains as outlined by the American College of Rheumatology: serological testing [e.g., for rheumatoid factor (RF) and anti-95 citrullinated protein antibody (ACPA)], physical examination for joint swelling and tenderness, 96 97 evaluation of symptom duration, and testing acute phase reactants like C-reactive protein (CRP) 98 (14, 15). While these diagnostic methods are effective for established OA and RA, respectively, 99 they are less reliable for detecting early-stage disease. Previous studies have defined early OA 100 as individuals with KL grades 0 or 1 plus frequent joint pain lasting at least 4 weeks (16, 17), while 101 early RA has been defined as treatment-naïve (i.e., no DMARD use) individuals with symptoms 102 for <6 months and ACPA of an average 231.1 U/mL (range 24-2613.5 U/mL) (18). However, 103 radiographic diagnosis of OA is dependent on identifying structural changes that are less apparent

It is made available under a CC-BY-NC-ND 4.0 International license .

in the early stages (11). For RA, serological markers like CRP lack specificity for RA-related
 inflammation and can be elevated in other conditions such as systemic lupus erythematosus or
 psoriatic arthritis (19, 20). Given these challenges, there is a need for biomarkers that can reliably
 detect and distinguish OA and RA in the early stages.

108

109 MicroRNAs have emerged as promising candidate biomarkers (21). These small non-coding RNA 110 molecules are abundant and stable in peripheral blood, exhibit resistance to degradation, and 111 show disease- and stage-specific profiles (22). Although previous studies have identified 112 microRNAs involved in both OA and RA (23-25), to date only three studies have explored circulating microRNAs in early OA or early RA individuals. Briefly, Ali et al. compared early to late 113 114 OA plasma utilizing microRNA-sequencing (16), Romo-García et al. compared early RA to healthy 115 control serum with microRNA microarray (18), and Cunningham et al. compared "at risk" RA to 116 healthy control serum using a microRNA multiplex panel (26). To the best of our knowledge, no 117 studies have compared circulating microRNAs in early OA and early RA alongside non-OA/RA.

118

119 Advances in sequencing technology and bioinformatic tools have made microRNA-sequencing 120 the current gold standard approach for unbiased and comprehensive microRNA profiling (27). Compared to methods such as microarray, sequencing enables high-throughput identification of 121 microRNAs and discovery of novel microRNA transcripts (28, 29). Novel microRNAs are detected 122 123 based on their predicted secondary structures and defined based on specific criteria (e.g., a lack 124 of sequence homology with other species) (30). As a result, novel microRNAs can be highly 125 specific to the biological contexts in which they are identified (29, 31). In this study, we aimed to 126 use sequencing and bioinformatics to identify known and novel circulating microRNA signatures in early OA and early RA individuals. 127

128

It is made available under a CC-BY-NC-ND 4.0 International license .

130 Methods

131

132 Study group characteristics

An overview of the study groups is shown in Figure 1A. Plasma samples were obtained from the 133 134 Henry Ford Health (HFH) OA Biobank, Nashville VA Medical Center, and the Osteoarthritis Initiative (OAI, https://nda.nih.gov/oai) for both microRNA-sequencing and validation experiments. 135 We used established definitions for early OA (16, 17) and early RA (18). The early OA group 136 137 included individuals with symptoms and knee KL grades of 0 or 1, as assessed by an orthopedic 138 surgeon. Of N=20 early OA samples, N=12 were used for sequencing and N=8 for validation. The 139 early RA group included treatment-naïve individuals with <6 months of RA symptoms in any joint, 140 as assessed by a rheumatologist. The measured ACPA levels in this group were 42 to 1196 U/mL. 141 which aligns with the previously reported range of 24 to 2613.5 U/mL for early RA (18). Of N=12 142 early RA samples. N=6 were used for sequencing and N=6 for validation. The non-OA/RA group 143 was obtained from the OAI "Control Cohort" and included individuals with no features of OA or RA. All N=44 non-OA/RA samples were used for sequencing. Clinicodemographic variables were 144 collected as shown in Table 1, including age, sex, race, and body mass index (BMI). Institutional 145 146 Review Board (IRB) approval was obtained from HFH (IRB #13995), the Nashville VA Medical Center (IRB #1643056 and IRB #1722175), and the OAI via the University of California, San 147 Francisco (FWA approval # 0000068; IRB approval # 10-00532). Written informed consent was 148 149 obtained from all participants before enrollment.

150

151 Plasma collection

Blood samples were collected in EDTA-coated vacutainers and fractionated by centrifugation as previously described (16). Plasma was aliquoted into 250 µL per cryovial, flash frozen with liquid nitrogen, and stored at -80°C until use. RNA was extracted from plasma using the miRNeasy Serum/Plasma Advanced Kit (QIAGEN Inc.) following the manufacturer's guidelines. ACPA was

It is made available under a CC-BY-NC-ND 4.0 International license .

156 quantified in diluted plasma (dilution factor = 4), using the Human ACPA ELISA kit (abx257273;

157 Abbexa LLC), following the manufacturer's guidelines. Absorbance was measured at 450 nm

158 using a plate reader (PerkinElmer).

159

160 MicroRNA-sequencing

161 MicroRNA-sequencing and data analysis were performed for N=62 samples, according to previously published protocols (16, 28, 31). Briefly, RNA isolated from plasma was sequenced 162 163 using a 75-base single-end read protocol at a depth of approximately 17 ± 2.5 million 164 reads/sample on an Illumina NextSeq2000 sequencer (Figure 1B). Raw microRNA sequences were aligned to miRBase v22.1 (32) and the human reference genome (vGRCh38; Figure 1C). 165 166 Next, we filtered for abundant microRNAs with at least 10 counts-per-million (CPM) in two or more 167 samples, and normalized counts to total counts (16, 28). Differential expression analysis between 168 groups was performed in a pairwise manner using a guasi-likelihood negative binomial model with 169 trended dispersions with the edgeR package (v3.40.2; Figure 1D,E).

170

171 Bioinformatics

Novel microRNA sequences were identified using miRDeep2 (30) as previously described (16, 172 31). Briefly, raw reads were aligned to the human reference genome (vGRCh38) with sequences 173 174 included in the miRBase v22.1 human and hairpin microRNA databases excluded. Candidate 175 novel microRNAs were subsequently filtered by significant randfold value (p<0.05), a measure of 176 microRNA secondary structure stability, and by lack of homology with known mature microRNA sequences in mice. Prioritized novel microRNA sequences were subjected to NCBI nucleotide 177 178 Basic Local Alignment Search Tool (BLASTN; https://blast.ncbi.nlm.nih.gov/Blast.cgi) against Homo sapiens sequences. The search considered 100% query cover, 100% identity match, and 179 180 no set E-value.

It is made available under a CC-BY-NC-ND 4.0 International license .

182 MicroRNA real-time polymerase chain reaction (RT-qPCR)

MicroRNA RT-qPCR was performed in N=8 early OA and N=6 early RA independent plasma samples (**Figure 1F**), as previously described (33, 34). Briefly, a poly(A) tail was added to the microRNA with poly(A) polymerase (M0276L; NEB), followed by reverse transcription (RT) for the synthesis of cDNA using poly(T)-containing RT primers. The resulting cDNA was amplified using a QuantStudio 7 Pro Real-Time PCR System (Applied Biosystems), with custom microRNA oligonucleotides (Sigma-Aldrich) as specified in **Supplemental Table 1** and SYBR Green dye (Bio-Rad). Hsa-miR-24-3p was used as an endogenous control as previously done (16, 28).

190

191 Statistical analyses

All data analysis was performed using R statistical software (v.4.2.0). For microRNA discovery and validation, a power calculation estimated a minimum sample size of N=6/group to detect a differential expression threshold of fold-change ± 2, at 80% power. Principal component analysis (PCA) was performed on variance-stabilized transformed counts. Heatmaps were plotted using z-score-transformed CPM. RT-qPCR data were analyzed using the delta-delta-Ct method (35). Statistical significance was determined by false discovery rate (FDR) correction ≤0.05 for microRNA-sequencing, and two-tailed Student's T-test for RT-qPCR analyses at p≤0.05.

199

200 <u>Results</u>

201

202 Exploratory analyses of microRNAs in early OA and early RA plasma

To discover circulating microRNAs dysregulated in either early OA or early RA (**Figure 1G**), we performed microRNA-sequencing on N=62 plasma samples as shown in **Table 1**. Samples were matched for clinicodemographic variables as closely as possible, though significant differences in age and race across groups were noted (**Table 1**). After sequencing, read alignment to miRBase and the human reference genome resulted in raw counts for 2656 mature microRNAs. Data

208 analyses were performed in a pairwise manner, leading to three comparisons: (1) early OA versus 209 early RA, (2) early OA versus non-OA/RA and (3) early RA versus non-OA/RA. First, we filtered 210 for microRNAs with >10 CPM in two or more samples (within each comparison), resulting in 285 211 abundant microRNAs for early OA versus early RA, 364 for early OA versus non-OA/RA, and 354 212 for early RA versus non-OA/RA. Next, we performed PCA to identify components that account for 213 the variance within the counts. PCA plots showed distinct clustering between early OA and both early RA (Figure 2A) and non-OA/RA (Figure 2B), while no clustering was observed between 214 215 early RA and non-OA/RA (Figure 2C). Despite the significant differences in age and race across 216 groups (Table 1), no clustering was observed when classifying samples by age, sex, BMI, or race (Supplemental Figure 1), suggesting that these variables did not significantly impact microRNA 217 218 counts. Following this, we performed unsupervised hierarchical clustering of microRNA counts for 219 each pairwise comparison. Using heatmaps to visualize the results, we observed patterns of high 220 and low levels of microRNAs in both the early OA versus early RA (Supplemental Figure 2A) and early OA versus non-OA/RA comparisons (Supplemental Figure 2B); however, no 221 222 appreciable patterns were observed in the early RA versus non-OA/RA comparison 223 (Supplemental Figure 2C). Finally, we performed pairwise differential expression analyses to 224 identify significant differences in microRNAs in each comparison. At FDR<0.05, we identified 170 225 differentially expressed (DE) microRNAs between early OA and early RA (Figure 2D) and 305 226 DE microRNAs for early OA versus non-OA/RA (Figure 2E); however, no significant differences 227 were found between early RA and non-OA/RA (Figure 2F). Taken together, these results suggest 228 there are distinct circulating microRNAs in early OA versus both early RA and non-OA/RA, but 229 not between early RA and non-OA/RA.

230

231 Stepwise filtering of microRNAs dysregulated in early OA and early RA

To systematically identify dysregulated microRNAs associated with early OA and early RA, we implemented a stepwise filtering approach. The first steps retained abundant microRNAs (**Figure**

234 **3A.** Criterion 1) and DE microRNAs (Figure 3A. Criterion 2) for each pairwise comparison, as described above. We then compared the lists of DE microRNAs to identify those that were shared 235 and found all 170 DE microRNAs identified in the early OA versus early RA comparison were also 236 237 dysregulated in the early OA versus non-OA/RA comparison. Since no additional DE microRNAs 238 were detected between early RA and non-OA/RA, we focused on the 170 DE microRNAs in early 239 OA versus both early RA and non-OA/RA (Figure 3A, Criterion 2). Next, we filtered for microRNAs that were consistently up- or downregulated across samples in a group relative to 240 their median levels in the comparison group (Figure 3A, Criterion 3). For early OA, 13 241 242 microRNAs were upregulated and 132 downregulated in 100% of samples compared to their median counts in early RA group. Of these, all 13 upregulated and 128 of the 132 downregulated 243 244 microRNAs showed the same trend when compared to median counts in the non-OA/RA group 245 (Figure 3A, Criterion 3). For early RA, 137 microRNAs were upregulated and 15 downregulated 246 in 100% of samples versus their median counts in the early OA group. Since no microRNAs met the 100% threshold in the early RA versus non-OA/RA comparison, we relaxed this threshold to 247 248 ≥83% of early RA samples and identified two upregulated (hsa-miR-11400, hsa-miR-21-5p) and 249 two downregulated (hsa-miR-660-5p, hsa-miR-29c-3p) microRNAs (Figure 3A, Criterion 3). 250 These four microRNAs represented our shortlisted panel for early RA (Supplemental Table 2). 251 To refine the list of microRNAs for early OA, we performed an additional filtering step to select microRNAs with average logCPM \geq 10 and logFC \geq 1 or \leq -2.5 in early OA versus early RA. This 252 253 resulted in a shortlisted panel of four upregulated (hsa-miR-144-3p, hsa-miR-486-3p, hsa-miR-254 486-5p, hsa-miR-16-5p) and four downregulated (hsa-miR-744-5p, hsa-miR-382-5p, hsa-miR-3074-5p, hsa-miR-142-3p) microRNAs for early OA (Figure 3A, Criterion 4; Supplemental 255 256 **Table 3**). In sum, this filtering approach shortlisted 12 microRNAs with distinct profiles in early OA and early RA plasma (Figure 3B). 257

258

259 MicroRNA validation in independent early OA and early RA samples

It is made available under a CC-BY-NC-ND 4.0 International license .

260 After shortlisting 12 microRNAs (Figure 3), we next sought to validate their levels in independent 261 plasma samples using RT-qPCR. We focused on early OA versus early RA as our most clinically relevant comparison and measured the levels of each microRNA in N=8 early OA and N=6 early 262 RA plasma samples (Supplemental Table 4). Of the 12 microRNAs, six showed patterns 263 264 consistent with our microRNA-sequencing results. Among these, hsa-miR-16-5p and hsa-miR-265 29c-3p were elevated in early OA (Figure 4A,B), while hsa-miR-774-5p, hsa-miR-382-5p, hsamiR-3074-5p, and hsa-miR-11400 were elevated in early RA (Figure 4C-F). The six remaining 266 267 microRNAs either did not reach statistical significance or showed trends opposite to our 268 sequencing data (Supplemental Figure 3). Overall, these results prioritize hsa-miR-16-5p, hsamiR-29c-3p, hsa-miR-774-5p, hsa-miR-382-5p, hsa-miR-3074-5p, and hsa-miR-11400 as six 269 270 circulating microRNAs that are different between early OA and early RA (Figure 1F).

271

272 Novel microRNA discovery in early OA and early RA

We next used established protocols to discover novel microRNAs in our sequencing dataset (16, 273 274 31). This approach identified 1257 unique predicted novel microRNA sequences that were 275 present in at least one early OA or early RA sample, had a randfold p-value of <0.05, and showed 276 no homology with known microRNA sequences in mice. To refine this list, we retained novel 277 microRNAs present in ≥50% of either early OA or early RA samples, resulting in three and ten 278 novel microRNAs, respectively (Table 2). BLASTN analysis confirmed the human origin of all 13 279 novel microRNA sequences, demonstrating 100% identity match and 100% guery coverage when 280 compared to Homo sapiens sequences. Looking for novel microRNAs that were enriched in early OA, we identified Novel miRNA EOA 2 in ≥75% of early OA samples and <25% of both early RA 281 282 and non-OA/RA samples (Table 2). Meanwhile, four novel microRNAs (Novel miRNA ERA 2, 3, 4, and 7) were present in \geq 50% of early RA samples, and completely absent in early OA samples 283 284 (**Table 2**). We therefore prioritized these five novel microRNAs as the most distinct between early OA and early RA. 285

It is made available under a CC-BY-NC-ND 4.0 International license .

286 Discussion

287

Detecting early OA and early RA in clinical settings can be challenging since current diagnostic 288 289 tools work best for established disease. Distinguishing early OA from early RA can also be 290 challenging given the overlap in the initial presentation. These challenges point to the need for 291 reliable, minimally invasive biomarkers to support accurate diagnosis and timely intervention. There is mounting evidence demonstrating the utility of non-coding RNAs as disease biomarkers 292 293 (21, 25). In this study, we explore the potential of circulating microRNAs by performing microRNA-294 sequencing on plasma samples from individuals with early OA, early RA, and non-OA/RA. We observe distinct patterns of microRNAs between early OA and both early RA and non-OA/RA, but 295 296 no significant differences between early RA and non-OA/RA. With stepwise filtering and real-time 297 PCR validation, we prioritize a panel of six known microRNAs and five novel microRNAs as 298 candidates to differentiate early OA from early RA.

299

300 Among the strengths of this study is the customized microRNA-sequencing analysis pipeline and 301 systematic filtering approach we applied (16, 31). A common pitfall of profiling studies is the 302 reliance on single thresholds, such as p-values or fold-changes, to select targets of interest. These thresholds can vary significantly between studies (36, 37), leading to irreproducible results: 303 304 moreover, this strategy risks prioritizing biomarker candidates with statistical significance but not 305 biological relevance. To overcome this, we designed a filtering approach to prioritize microRNAs 306 with properties that would make strong biomarkers. First, we selected high abundance 307 microRNAs to increase the likelihood their presence would be detectable in a general population. 308 This is important because many microRNAs have low to no counts in a sequencing dataset, so 309 while their fold change may be statistically significant, they may not play a biologically relevant 310 role (38). Second, we performed pairwise differential expression analyses to consider each Group 1 to both Groups 2 and 3. This allowed us to prioritize microRNAs in early OA versus both early 311

It is made available under a CC-BY-NC-ND 4.0 International license .

312 RA and non-OA/RA, and to find that microRNAs in early RA were different compared to early OA. 313 not but non-OA/RA. Third, to counter the heterogeneity inherent to human biospecimens, we selected DE microRNAs that showed an increase or decrease across the majority of individual 314 315 samples in a group. This allowed us to prioritize microRNAs with consistent trends and a greater 316 likelihood of being reproducible. Interestingly, nearly all the microRNAs in the early OA group 317 showed exclusive up- or downregulation compared to both early RA and non-OA/RA, suggesting a robust microRNA signature for early OA. As a fourth and final step to refine this early OA 318 319 signature, we applied thresholds based on abundance and fold-change to retain microRNAs with 320 the greatest difference between groups. Importantly, these filtering criteria were designed to prioritize microRNAs with biomarker potential, which means other criteria may be more 321 322 appropriate for microRNA studies with different objectives.

323

324 Previous studies have reported circulating microRNAs in early OA and early RA, including seven 325 plasma microRNAs associated with early OA (16) and seven serum microRNAs associated with 326 early RA (18) or "at risk" RA (26). Notably, there was no overlap between these 14 microRNAs 327 and the microRNAs shortlisted in the current study; however, 12 of the 14 microRNAs showed a 328 significant difference in at least one of our three pairwise comparisons. From Ali et al. (16), seven 329 microRNAs were elevated in early versus late radiographic knee OA plasma; among these, four 330 were significantly downregulated in our early OA samples compared to both early RA and non-OA/RA (hsa-miR-191-3p, hsa-miR-199a-5p, hsa-miR-335-5p, and hsa-miR-671-3p). From 331 332 Romo-García et al. (18), hsa-miR-361-5p was reported to be elevated in early RA serum compared to non-RA controls, and it was significantly upregulated in our early RA samples 333 compared to early OA, but not to non-OA/RA. From Cunningham et al. (26), six microRNAs were 334 335 upregulated in serum from "at risk" RA individuals (symptomatic with positive ACPA or RF but 336 without clinical synovitis or raised CRP) versus healthy controls (26). Of these, five were found to be significantly upregulated in our early RA samples compared to early OA, but not to non-OA/RA. 337

It is made available under a CC-BY-NC-ND 4.0 International license .

338 Overall, the inconsistencies between previous literature and our findings are not unexpected given 339 the variations in study groups, sample types, and analytical approaches. This underscores the 340 need for standardized methodologies in biomarker discovery.

341

Given their lack of previous documentation, novel microRNAs are inherently valuable as potential disease-specific biomarkers (30). Ali et al. (16) previously reported four novel microRNAs that were enriched in early OA. Of these, two sequences (novel_miRNA_2 and novel_miRNA_3) were found in our dataset but did not meet our filtering criteria, as they were present in <50% of early OA samples. To our knowledge, no studies to date have reported novel microRNAs in early RA. We present four novel microRNA candidates that merit further investigation as biomarkers for early RA, including characterization to verify their authenticity as microRNAs.

349

350 Relationships between circulating microRNAs and pathological processes have been reported in arthritis (39, 40), suggesting circulating microRNAs can reflect local disease status. In early OA 351 352 plasma, we found elevated levels of hsa-miR-16-5p and hsa-miR-29c-3p. Previous studies have reported increased levels of hsa-miR-16 in OA plasma versus non-OA controls (41), and 353 354 decreased levels in early RA serum versus established RA (42). It is also upregulated in serum from RA individuals following treatment with anti-inflammatory agents (43). In terms of tissue 355 356 functions, hsa-miR-16-5p has mechanistic connections to cartilage degradation in OA (41). While 357 hsa-miR-29c-3p has not been previously explored in OA or RA circulation, elevated levels are 358 found in late OA versus early OA synovial fluid (44). These findings are not directly comparable 359 to ours, but inverse trends between circulating and local microRNA levels have been previously reported (40, 45). In early RA plasma, we found elevated levels of hsa-miR-382-5p, hsa-miR-774-360 5p, hsa-miR-3074-5p, and hsa-miR-11400. Little is known about the role of these microRNAs in 361 362 arthritis, with only one study examining the behavior of hsa-miR-382-5p in RA fibroblast-like

It is made available under a CC-BY-NC-ND 4.0 International license .

363 synoviocytes (46). As such, the current study is the first to propose these four microRNAs as
 364 potential biomarkers for early RA.

365

To note the limitations of this study, our sample sizes were sufficient to detect significant 366 367 microRNAs at FDR≤0.05 but were not sufficient to support the testing of predictive models (47, 48). Future studies with larger cohorts are required to evaluate the sensitivity and specificity of 368 our prioritized microRNAs as biomarkers for early OA and early RA. Second, the microRNA 369 370 signature we identify for early OA appears to be more robust than that identified for early RA, 371 given the lack of differences between early RA and non-OA/RA. While previous studies report differences between early RA and healthy controls (18, 26), the utility of our study lies primarily in 372 373 the comparison between early RA and early OA to ultimately support differentiation of these cases 374 in clinical settings. Finally, we did not define OA by the number of joints involved, or RA by the specific joints involved, which may influence microRNA patterns. Future microRNA biomarker 375 376 discovery studies are needed to compare single-joint knee OA versus RA, and RA versus other 377 inflammatory conditions with overlapping serological markers.

378

379 **Conclusion**

To our knowledge, this is the first study that profiles circulating microRNAs in early OA, early RA, and non-OA/RA individuals using microRNA-sequencing. With a tailored approach to data analysis, we prioritized 11 circulating microRNAs (six known and five novel) that are associated with early OA and early RA. These findings suggest there is potential for circulating microRNAs to serve as minimally invasive biomarkers for early OA and early RA, including as composite biomarkers on panels that include proteins. With further research in larger cohorts, these microRNAs can be developed into a diagnostic test to improve arthritis care.

387

It is made available under a CC-BY-NC-ND 4.0 International license .

389 List of abbreviations

- 390
- 391 ACPA: Anti-citrullinated protein antibody
- 392 BLASTN: nucleotide Basic Local Alignment Search Tool
- 393 BMI: Body mass index
- 394 CPM: Counts per million
- 395 CRP: C-reactive protein
- 396 DE: Differentially expressed
- 397 DMARDs: Disease-modifying anti-rheumatic drugs
- 398 FC: Fold-change
- 399 FDR: False discovery rate
- 400 KL: Kellgren-Lawrence
- 401 PCA: Principal component analysis
- 402 RA: Rheumatoid arthritis
- 403 RF: Rheumatoid factor
- 404 RT-qPCR: Real time polymerase chain reaction
- 405 OA: Osteoarthritis
- 406

407 **Declarations**

408

409 Ethics approval and consent to participate

410 All participants provided written informed consent to be included in this study. The study protocol

- 411 followed guidelines set by the Henry Ford Health Institutional Review Board (IRB #13995).
- 412 Additional ethics approval was provided by the VA Tennessee Healthcare System (IRB #1643056
- and IRB #1722175), and the OAI via University of California, San Francisco (FWA approval #
- 414 00000068; IRB approval # 10-00532).

It is made available under a CC-BY-NC-ND 4.0 International license .

415

416 Availability of data and materials

- 417 The microRNA-sequencing datasets generated during this study were deposited in the Gene
- 418 Expression Omnibus database and will be released following peer-reviewed publication.
- 419
- 420 Funding
- 421 Funding for this study was provided by competitive grants awarded to SAA from the Pfizer Global
- 422 Medical Grants (#72538937) and the University of Toronto McLaughlin Centre Accelerator Grant
- 423 (#MC-2022-06), and to MO by the Merit award (#I01CX002356) from the US Department of
- Veterans Affairs and the Discovery award (#HT9425-23-1-0044) from the Department of Defense,
- 425 Peer Reviewed Medical Research Program.

426

427 Competing Interests

428 SAA declares that she has filed a US Provisional Patent Application no. 63/033,463 titled 429 *Circulating MicroRNAs in Knee Osteoarthritis and Uses Thereof.* All other authors declare no 430 competing interests.

431

432 Author contributions

433 MB, TGW, and SAA were involved in study conception and design. MB and TGW performed 434 experimental work and data acquisition. JD, VM, MO, PY, AA, AM, MB and TGW contributed to 435 biospecimen collection. MB, TGW, and SAA performed data analysis, interpretation, and drafted 436 the manuscript. All authors contributed to manuscript revisions and approved the final version.

437

438

439

It is made available under a CC-BY-NC-ND 4.0 International license .

441 **References**

- 1. Barbour KE, Helmick CG, Boring M, Brady TJ. Vital Signs: Prevalence of Doctor-
- Diagnosed Arthritis and Arthritis-Attributable Activity Limitation United States, 2013-2015.
- 444 MMWR Morb Mortal Wkly Rep. 2017;66(9):246-53.
- 445 2. Steinmetz JD, Culbreth GT, Haile LM, Rafferty Q, Lo J, Fukutaki KG, et al. Global,
- regional, and national burden of osteoarthritis, 1990–2020 and projections to 2050: a systematic
- analysis for the Global Burden of Disease Study 2021. The Lancet Rheumatology.
- 448 2023;5(9):e508-e22.
- 449 3. Long H, Liu Q, Yin H, Wang K, Diao N, Zhang Y, et al. Prevalence Trends of Site-
- 450 Specific Osteoarthritis From 1990 to 2019: Findings From the Global Burden of Disease Study
- 451 2019. Arthritis Rheumatol. 2022;74(7):1172-83.
- 452 4. Kurdi AJ, Voss BA, Tzeng TH, Scaife SL, El-Othmani MM, Saleh KJ. Rheumatoid
- 453 Arthritis vs Osteoarthritis: Comparison of Demographics and Trends of Joint Replacement Data
- 454 from the Nationwide Inpatient Sample. Am J Orthop (Belle Mead NJ). 2018;47(7).
- Loeser RF, Goldring SR, Scanzello CR, Goldring MB. Osteoarthritis: a disease of the
 joint as an organ. Arthritis Rheum. 2012;64(6):1697-707.
- 457 6. Ospelt C, Gay S, Klein K. Epigenetics in the pathogenesis of RA. Semin Immunopathol.
 458 2017;39(4):409-19.
- 459 7. Buckwalter JA, Mankin HJ. Articular cartilage: degeneration and osteoarthritis, repair,
 460 regeneration, and transplantation. Instr Course Lect. 1998;47:487-504.
- 461 8. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet.
- 462 2016;388(10055):2023-38.
- 463 9. Mandl LA. Osteoarthritis year in review 2018: clinical. Osteoarthritis Cartilage.
- 464 2019;27(3):359-64.
- 10. Ostrowska M, Maslinski W, Prochorec-Sobieszek M, Nieciecki M, Sudol-Szopinska I.
- 466 Cartilage and bone damage in rheumatoid arthritis. Reumatologia. 2018;56(2):111-20.

It is made available under a CC-BY-NC-ND 4.0 International license .

467 11. Kohn MD, Sassoon AA, Fernando ND. Classifications in Brief: Kellgren-Lawrence

468 Classification of Osteoarthritis. Clin Orthop Relat Res. 2016;474(8):1886-93.

469 12. Kolasinski SL, Neogi T, Hochberg MC, Oatis C, Guyatt G, Block J, et al. 2019 American

470 College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of

the Hand, Hip, and Knee. Arthritis Care Res (Hoboken). 2020;72(2):149-62.

472 13. Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, et al. 2021

473 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.

474 Arthritis Care Res (Hoboken). 2021;73(7):924-39.

475 14. Fc A. The American Rheumatism Association 1987 revised criteria for the classification
476 of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-24.

477 15. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, 3rd, et al. 2010

478 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European

League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569-81.

480 16. Ali SA, Gandhi R, Potla P, Keshavarzi S, Espin-Garcia O, Shestopaloff K, et al.

481 Sequencing identifies a distinct signature of circulating microRNAs in early radiographic knee
482 osteoarthritis. Osteoarthritis Cartilage. 2020.

Luyten FP, Bierma-Zeinstra S, Dell'Accio F, Kraus VB, Nakata K, Sekiya I, et al. Toward
classification criteria for early osteoarthritis of the knee. Semin Arthritis Rheum. 2018;47(4):45763.

486 18. Romo-Garcia MF, Bastian Y, Zapata-Zuniga M, Macias-Segura N, Castillo-Ortiz JD,

487 Lara-Ramirez EE, et al. Identification of putative miRNA biomarkers in early rheumatoid arthritis

by genome-wide microarray profiling: A pilot study. Gene. 2019;720:144081.

489 19. Yildirim K, Karatay S, Melikoglu MA, Gureser G, Ugur M, Senel K. Associations between

490 acute phase reactant levels and disease activity score (DAS28) in patients with rheumatoid

491 arthritis. Ann Clin Lab Sci. 2004;34(4):423-6.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 492 20. Suresh E. Diagnosis of early rheumatoid arthritis: what the non-specialist needs to know.
- 493 J R Soc Med. 2004;97(9):421-4.
- 494 21. Rocha FAC, Ali SA. Soluble biomarkers in osteoarthritis in 2022: year in review.
- 495 Osteoarthritis Cartilage. 2023;31(2):167-76.
- 496 22. Bottani M, Banfi G, Lombardi G. The Clinical Potential of Circulating miRNAs as
- 497 Biomarkers: Present and Future Applications for Diagnosis and Prognosis of Age-Associated
- 498 Bone Diseases. Biomolecules. 2020;10(4).
- 499 23. Zhang M, Lygrisse K, Wang J. Role of MicroRNA in Osteoarthritis. J Arthritis. 2017;6(2).
- 500 24. Evangelatos G, Fragoulis GE, Koulouri V, Lambrou GI. MicroRNAs in rheumatoid
- arthritis: From pathogenesis to clinical impact. Autoimmun Rev. 2019;18(11):102391.
- 502 25. Ali SA, Peffers MJ, Ormseth MJ, Jurisica I, Kapoor M. The non-coding RNA interactome
- in joint health and disease. Nat Rev Rheumatol. 2021;17(11):692-705.
- 26. Cunningham CC, Wade S, Floudas A, Orr C, McGarry T, Wade S, et al. Serum miRNA
- 505 Signature in Rheumatoid Arthritis and "At-Risk Individuals". Front Immunol. 2021;12:633201.
- 506 27. Dedeoglu BG. High-throughput approaches for microRNA expression analysis. Methods
 507 Mol Biol. 2014;1107:91-103.
- 508 28. Ali SA, Espin-Garcia O, Wong AK, Potla P, Pastrello C, McIntyre M, et al. Circulating
- 509 microRNAs differentiate fast-progressing from slow-progressing and non-progressing knee
- 510 osteoarthritis in the Osteoarthritis Initiative cohort. Ther Adv Musculoskelet Dis.
- 511 2022;14:1759720X221082917.
- 512 29. Wake C, Labadorf A, Dumitriu A, Hoss AG, Bregu J, Albrecht KH, et al. Novel microRNA
- 513 discovery using small RNA sequencing in post-mortem human brain. BMC Genomics.
- 514 2016;17(1):776.
- 515 30. Friedlander MR, Mackowiak SD, Li N, Chen W, Rajewsky N. miRDeep2 accurately
- 516 identifies known and hundreds of novel microRNA genes in seven animal clades. Nucleic Acids
- 517 Res. 2012;40(1):37-52.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 518 31. Potla P, Ali SA, Kapoor M. A bioinformatics approach to microRNA-sequencing analysis.
- 519 Osteoarthritis and Cartilage Open. 2021;3(1).
- 520 32. Kozomara A, Griffiths-Jones S. miRBase: annotating high confidence microRNAs using
- 521 deep sequencing data. Nucleic Acids Res. 2014;42(Database issue):D68-73.
- 33. Busk PK. A tool for design of primers for microRNA-specific quantitative RT-qPCR. BMC
 Bioinformatics. 2014;15:29.
- 524 34. Balcells I, Cirera S, Busk PK. Specific and sensitive quantitative RT-PCR of miRNAs
- with DNA primers. BMC Biotechnol. 2011;11:70.
- 526 35. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time
- 527 quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402-8.
- 528 36. Zhou Y, Wang Z, Chen X, Zhang J, Yang L, Liu S, et al. Identification of differentially
- 529 expressed miRNAs and mRNAs in synovial of osteoarthritis via RNA-sequencing. BMC Med
- 530 Genet. 2020;21(1):46.
- 531 37. Maunder D, Brown PM, Barron-Millar B, Lendrem DW, Naamane N, Macdonald J, et al.
- 532 Micro-RNA content of circulating extracellular vesicles in early rheumatoid arthritis as
- biomarkers and mediators of methotrexate efficacy. Rheumatology (Oxford). 2024;63(8):2259-
- 534 67.
- 535 38. Chen Y, Lun AT, Smyth GK. From reads to genes to pathways: differential expression
- analysis of RNA-Seq experiments using Rsubread and the edgeR quasi-likelihood pipeline.
- 537 F1000Res. 2016;5:1438.
- 39. Ramos YFM, Coutinho de Almeida R, Lakenberg N, Suchiman E, Mei H, Kloppenburg
- 539 M, et al. Circulating MicroRNAs Highly Correlate to Expression of Cartilage Genes Potentially
- 540 Reflecting OA Susceptibility-Towards Identification of Applicable Early OA Biomarkers.
- 541 Biomolecules. 2021;11(9).
- 40. Wilson TG, Baghel M, Kaur N, Moutzouros V, Davis J, Ali SA. Characterization of miR-
- 543 335-5p and miR-335-3p in human osteoarthritic tissues. Arthritis Res Ther. 2023;25(1):105.

It is made available under a CC-BY-NC-ND 4.0 International license .

544 41. Borgonio Cuadra VM, Gonzalez-Huerta NC, Romero-Cordoba S, Hidalgo-Miranda A,

545 Miranda-Duarte A. Altered expression of circulating microRNA in plasma of patients with

546 primary osteoarthritis and in silico analysis of their pathways. PLoS One. 2014;9(6):e97690.

547 42. Dunaeva M, Blom J, Thurlings R, Pruijn GJM. Circulating serum miR-223-3p and miR-

548 16-5p as possible biomarkers of early rheumatoid arthritis. Clin Exp Immunol. 2018;193(3):376-

549 85.

43. Castro-Villegas C, Perez-Sanchez C, Escudero A, Filipescu I, Verdu M, Ruiz-Limon P, et

al. Circulating miRNAs as potential biomarkers of therapy effectiveness in rheumatoid arthritis

552 patients treated with anti-TNFalpha. Arthritis Res Ther. 2015;17(1):49.

553 44. Li YH, Tavallaee G, Tokar T, Nakamura A, Sundararajan K, Weston A, et al.

Identification of synovial fluid microRNA signature in knee osteoarthritis: differentiating early-

and late-stage knee osteoarthritis. Osteoarthritis Cartilage. 2016;24(9):1577-86.

45. Malakootian M, Gholipour A, Oveisee M. Comprehensive bioinformatics analysis of key

miRNAs and signaling pathways in the body fluids of human knee osteoarthritis. Cell Mol Biol

558 (Noisy-le-grand). 2023;69(12):88-97.

46. Meng D, Pan W, Li J. The Role of miR-382-5p in Rheumatoid Arthritis: An In Vitro Study

with Fibroblast-Like Synoviocytes. Journal of Biomaterials and Tissue Engineering.

561 2020;10:169-75.

562 47. Kok MGM, de Ronde MWJ, Moerland PD, Ruijter JM, Creemers EE, Pinto-Sietsma SJ.

563 Small sample sizes in high-throughput miRNA screens: A common pitfall for the identification of

miRNA biomarkers. Biomol Detect Quantif. 2018;15:1-5.

48. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the
number of events per variable in logistic regression analysis. J Clin Epidemiol.

567 1996;49(12):1373-9.

568

It is made available under a CC-BY-NC-ND 4.0 International license .



Figure 1. Overview of study design. (A) The study included three groups defined by predetermined inclusion and exclusion criteria. (B) MicroRNA-sequencing was performed on N=62 plasma samples. (C) Data were processed using an established pipeline (31). (D) Exploratory analyses included principal component analysis (PCA). (E) Stepwise filtering was performed to shortlist microRNAs. (F) Validation experiments in N=14 independent samples prioritized six microRNAs. (G) Dysregulated known and novel microRNAs may be used to distinguish individuals with early OA or early RA.

It is made available under a CC-BY-NC-ND 4.0 International license .



579 Figure 2. Distinct circulating microRNAs are present in early OA and early RA. (A-C)

Principal component analyses showing clustering of samples when stratified by cohort. Each point
represents a sample. Each axis represents the percentage variance for the principal component
(PC). (D-F) Volcano plots showing differentially expressed microRNAs in each comparison, with

- 583 FDR≤0.05 (horizontal line). Each dot represents a microRNA.

- . -

It is made available under a CC-BY-NC-ND 4.0 International license .



Figure 3. Stepwise filtering identified microRNAs dysregulated in early OA and early RA.

(A) Four sequential filtering criteria were applied to identify dysregulated microRNAs. The brown box shows filtering for microRNAs in early OA versus early RA and non-OA/RA. The purple box shows filtering for microRNAs in early RA versus early OA and non-OA/RA. (B) Heatmap depicting plasma levels of 12 microRNAs dysregulated in early OA and early RA. Z-scores represent standardized microRNA counts, with green indicating higher levels and red indicating lower levels.

It is made available under a CC-BY-NC-ND 4.0 International license .

620



Figure 4. RT-qPCR validation of six microRNAs in early OA and early RA. RT-qPCR was performed in N=8 early OA and N=6 early RA independent plasma samples. Relative microRNA levels represent fold-change in early RA (purple) normalized to average levels in early OA (brown). *p<0.05; error bars = 95% confidence interval. (A,B) Two microRNAs were upregulated in early OA versus early RA. (C-F) Four microRNAs were upregulated in early RA versus early OA.

630

- 631
- 632

It is made available under a CC-BY-NC-ND 4.0 International license .

Cohort	Early OA	Early RA	Non-OA/RA	p-value
Inclusion criteria	Individuals with symptomatic knee OA and KL grade 0 or 1 as diagnosed by an orthopedic surgeon. ¹⁶	Treatment-naïve individuals with <6 months of RA symptoms as diagnosed by a rheumatologist; ACPA = 42-1196 IU/mL. ¹⁸	Individuals with no history of arthritis.	-
N 12 6		44	-	
Sex (female) N (%)	6 (50.0)	6 2 22 (50.0) (33.3) (50.0)		0.43
Race (white) N (%)	12 (100.0)	4 (66.6)	42 (95.5)	<0.05
Age (years) Mean (SD)	49 (11.7)	56 (14.3)	57 (7.7)	<0.05
BMI (kg/m²) Mean (SD)	28 (4.9)	27 (3.9)	26 (2.8)	0.41

635 Table 1. Characterization of the three study groups used for microRNA-sequencing. P-

value shows the significance between groups assessed by one-way ANOVA for continuous

variables and Chi-square test for categorical variables. KL = Kellgren-Lawrence; ACPA = Anti-

638 citrullinated protein antibody; SD = standard deviation; BMI = body mass index.

It is made available under a CC-BY-NC-ND 4.0 International license .

Crown	Nama	Samuanaa	Proportion			
Group	Name Sequence		Early OA	Early RA	Non-OA/RA	
	Novel miRNA EOA 1	uaagagggacggaggagg	0.50	0.33	0.40	
Early OA	Novel miRNA EOA 2	gaugccugggaguugcgaucug	0.75	0.17	0.06	
	Novel miRNA EOA 3	gacgcggcggcgggcggca	0.50	0.17	0.32	
	Novel miRNA ERA 1	uuaagagggacggaggagg	0.17	0.50	0.34	
	Novel miRNA ERA 2	uguaagugagaagcaaaagugg	0.00	0.50	0.38	
	Novel miRNA ERA 3	uggggauagagcauugcc	0.00	0.50	0.12	
	Novel miRNA ERA 4	uacugggauauuuggagcuucu	0.00	0.50	0.20	
Early BA	Novel miRNA ERA 5	guugggaguuuggcuggg	0.08	0.67	0.24	
	Novel miRNA ERA 6	gguuccauaguguaguggu	0.17	0.67	0.22	
	Novel miRNA ERA 7	gggaaacucugguggaag	0.00	0.50	0.36	
	Novel miRNA ERA 8	caugaauggauuaaugag	0.25	0.67	0.48	
	Novel miRNA ERA 9	cagagauagggauguauc	0.17	0.67	0.16	
	Novel miRNA ERA 10	agacgcggcggcgggcgg	0.25	0.67	0.44	

Table 2. MicroRNA-sequencing identified five novel microRNAs enriched in early OA and

early RA. List of all novel microRNA sequences found in \geq 50% of early OA or early RA samples.

Proportion = % of samples in each group that have the novel microRNA sequence. Bold = novel

654 microRNAs prioritized for early OA and early RA.

_ _ _ _

It is made available under a CC-BY-NC-ND 4.0 International license .

664 Supplemental display items



Supplemental Figure 1. No distinct clustering is observed when microRNA-sequencing data are stratified by age, sex, BMI, or race. Principal component analysis plots of microRNAsequencing data stratified by (A) age, (B) sex, (C) BMI (<25 kg/m² = normal; 25-30 kg/m² = overweight; >30 kg/m² = obese), and (D) race. Each dot represents a sample. Each axis represents percentage variance for the principal component (PC).

It is made available under a CC-BY-NC-ND 4.0 International license .



Supplemental Figure 2. Expression profiles of microRNAs in pairwise comparisons. 586 Heatmaps depicting unsupervised hierarchical clustering of microRNAs in individual samples of 587 each pairwise comparison: (A) early OA versus early RA, (B) early OA versus non-OA/RA, and 588 (C) early RA versus non-OA/RA. Z-scores represent standardized microRNA counts, with green 589 indicating higher levels and red indicating lower levels.

It is made available under a CC-BY-NC-ND 4.0 International license .





Supplemental Figure 3. RT-qPCR for six microRNAs in early OA and early RA showing results inconsistent with sequencing data. RT-qPCR was performed in N=8 early OA and N=6 early RA independent plasma samples. Relative microRNA levels represent fold-change in early RA (purple) normalized to average levels in early OA (brown). Significance is denoted by a horizontal bar with *p<0.05 or NS = non-significant. Error bars = 95% confidence interval.</p>

- 711
- 712
- 713
- 714
- 715
- /10
- 716

It is made available under a CC-BY-NC-ND 4.0 International license .

Primer name	Primer Sequence (5'-3')
hsa-miR-16-5p	TCGCTTAGCAGCACGTAAATA
hsa-miR-21-5p	TCGCTTAGCTTATCAGACTGA
hsa-miR-24-3p	TGGCTCAGTTCAGCAGGAACAG
hsa-miR-29c-3p	TCGCTTAGCACCATTTGAAAT
hsa-miR-142-3p	TCGCTTGTAGTGTTTCCTACTT
hsa-miR-144-3p	TCGCTTACAGTATAGATGA
hsa-miR-382-5p	TCGCTGAAGTTGTTCGTGGTG
hsa-miR-486-3p	TCGCTCGGGGCAGCTCAGTA
hsa-miR-486-5p	TCGCTTCCTGTACTGAGCTGC
hsa-miR-660-5p	TCGCTTACCCATTGCATATCG
hsa-miR-744-5p	TCGCTTGCGGGGCTAGGGCTA
hsa-miR-3074-5p	TCGCTGTTCCTGCTGAACTG
hsa-miR-11400	TCGCTTCGGCTGTGTATCTCT
Oligo-dT adapter	GCATAGACCTGAATGGCGGTAAGGGTGT
primer	GGTAGGCGAGACATTTTTTTTTTTTTTTTTTTT
Universal microRNA reverse primer	GCATAGACCTGAATGGCGGTA

719 Supplemental Table 1. List of primers for microRNA RT-qPCR.

It is made available under a CC-BY-NC-ND 4.0 International license .

723

MioroPNA	Directionality in Early RA	Early RA versus Early OA				Early RA versus Non-OA/RA			
MICIORINA		logFC	logCPM	FDR	Proportion	logFC	logCPM	FDR	Proportion
hsa-miR-11400	Up	3.27	4.81	0.02	1.00	0.03	5.95	0.99	0.83
hsa-miR-21-5p	Up	1.26	10.50	0.00	1.00	0.28	10.96	0.41	0.83
hsa-miR-660-5p	Down	-0.95	7.76	0.00	1.00	-0.46	7.51	0.19	0.83
hsa-miR-29c-3p	Down	-0.77	8.35	0.02	1.00	-0.55	8.30	0.19	0.83

725	Supplemental Table 2. Four microRNAs prioritized in early RA versus early OA and non-
726	OA/RA. For directionality, "Up" reflects upregulation while "Down" reflects downregulation in early
727	RA versus early OA or non-OA/RA. For logFC, >0 reflects upregulation while ≤0 reflects
728	downregulation in early RA versus early OA or non-OA/RA. For FDR, ≤0.05 represents
729	statistically significant differential expression in the pairwise comparison. For proportion, values
730	represent the percentage of samples with logCPM either greater than (for upregulated
731	microRNAs) or less than (for downregulated microRNAs) the median logCPM of the comparison
732	group.
733	
734	
735	
736	
737	
738	
739	
740	
741	
742	
743	

It is made available under a CC-BY-NC-ND 4.0 International license .

7	4	4
	_	_

MieroDNA	Directionality in Early OA	Early OA versus Early RA				Early OA versus Non-OA/RA			
MICTORINA		logFC	logCPM	FDR	Proportion	logFC	logCPM	FDR	Proportion
hsa-miR-144-3p	Up	1.84	11.34	0.000	1.00	2.08	10.40	0.000	1.00
hsa-miR-486-3p	Up	1.61	13.39	0.000	1.00	2.36	12.31	0.000	1.00
hsa-miR-486-5p	Up	1.34	15.10	0.002	1.00	2.20	14.05	0.000	1.00
hsa-miR-16-5p	Up	1.27	18.83	0.000	1.00	1.67	18.03	0.000	1.00
hsa-miR-744-5p	Down	-2.88	10.38	0.000	1.00	-3.14	11.56	0.000	1.00
hsa-miR-382-5p	Down	-2.91	10.28	0.004	1.00	-2.83	11.14	0.000	1.00
hsa-miR-142-3p	Down	-2.90	10.08	0.000	1.00	-3.56	11.65	0.000	1.00
hsa-miR-3074-5p	Down	-2.61	10.93	0.000	1.00	-2.87	12.06	0.000	1.00

Supplemental Table 3. Eight microRNAs prioritized in early OA versus early RA and non-**OA/RA.** For directionality, "Up" reflects upregulation while "Down" reflects downregulation in early OA versus early RA or non-OA/RA. For logFC, >0 reflects upregulation while ≤0 reflects downregulation in early OA versus early RA or non-OA/RA. For FDR, ≤0.05 represents statistically significant differential expression in the pairwise comparison. For proportion, values represent the percentage of samples with logCPM either greater than (for upregulated microRNAs) or less than (for downregulated microRNAs) the median logCPM of the comparison group.

It is made available under a CC-BY-NC-ND 4.0 International license .

Cohort	Early OA	Early RA	p-value
Ν	8	6	-
Sex (female)	2	2	1
N (%)	(25)	(33.3)	
Race (white)	8	5	0.89
N (%)	(100)	(83.3)	
Age (years)	24	63	<0.05
Mean (SD)	(5.3)	(9.4)	
BMI (kg/m²)	30	26	0.30
Mean (SD)	(8.5)	(2.9)	

764 Supplemental Table 4. Characterization of the two study groups used for microRNA RT-

qPCR. N = sample size; SD = standard deviation; BMI = body mass index.